Article
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.
Science translational medicine - 1 Mar 2017
Roh Whijae, Chen Pei-Ling, Reuben Alexandre, Spencer Christine N, Prieto Peter A, Miller John P, Gopalakrishnan Vancheswaran, Wang Feng, Cooper Zachary A, Reddy Sangeetha M, Gumbs Curtis, Little Latasha, Chang Qing, Chen Wei-Shen, Wani Khalida, De Macedo Mariana Petaccia, Chen Eveline, Austin-Breneman Jacob L, Jiang Hong, Roszik Jason, Tetzlaff Michael T, Davies Michael A, Gershenwald Jeffrey E, Tawbi Hussein, Lazar Alexander J, Hwu Patrick, Hwu Wen-Jen, Diab Adi, Glitza Isabella C, Patel Sapna P, Woodman Scott E, Amaria Rodabe N, Prieto Victor G, Hu Jianhua, Sharma Padmanee, Allison James P, Chin Lynda, Zhang Jianhua, Wargo Jennifer A, Futreal P Andrew
Abstract excerpt
Immune checkpoint blockade produces clinical benefit in many patients. However, better biomarkers of response are still needed, and mechanisms of resistance remain incompletely understood. To address this, we recently studied a cohort of melanoma patients treated with sequential checkpoint blockade against cytotoxic T lymphocyte antigen-4 (CTLA-4) followed by programmed death receptor-1 (PD-1) and identified...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.